Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code effective Apr 01, 2021
HCPCS Section
Miscellaneous Services (Temporary Codes)
Q2053 is a valid 2026 HCPCS code meaning Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose or (Brexucabtagene car pos t) for short. HCPCS Q2053 has been effective since 04/01/2021 and applies to Medical care.
|
HCPCS Level II Code Section Q - Miscellaneous Services (Temporary Codes) |
|
| HCPCS Code | Q2053 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
51 - Drugs
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1E - Other drugs |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | 1 - Medical care |
| Effective date | Effective Apr 01, 2021 |
| Date added | Added Apr 01, 2021 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.